Research ExplorerPublicationsCucurbitacin B, a novel in vivo potentiator of gemcitabine w...

Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer.

Standard

Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer. / Iwanski, Gabriela B; Lee, Dhong H; En-Gal, Shlomit; Doan, Ngan B; Castor, Brandon; Vogt, Marco; Toh, Melvin; Bokemeyer, Carsten; Said, Jonathan W; Thoennissen, Nils H; Koeffler, H Phillip.

In: BRIT J PHARMACOL, Vol. 160, No. 4, 4, 2010, p. 998-1007.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Iwanski, GB, Lee, DH, En-Gal, S, Doan, NB, Castor, B, Vogt, M, Toh, M, Bokemeyer, C, Said, JW, Thoennissen, NH & Koeffler, HP 2010, 'Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer.', BRIT J PHARMACOL, vol. 160, no. 4, 4, pp. 998-1007. <http://www.ncbi.nlm.nih.gov/pubmed/20590594?dopt=Citation>

APA

Iwanski, G. B., Lee, D. H., En-Gal, S., Doan, N. B., Castor, B., Vogt, M., Toh, M., Bokemeyer, C., Said, J. W., Thoennissen, N. H., & Koeffler, H. P. (2010). Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer. BRIT J PHARMACOL, 160(4), 998-1007. [4]. http://www.ncbi.nlm.nih.gov/pubmed/20590594?dopt=Citation

Vancouver

Iwanski GB, Lee DH, En-Gal S, Doan NB, Castor B, Vogt M et al. Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer. BRIT J PHARMACOL. 2010;160(4):998-1007. 4.

Bibtex

@article{cae330ee39984cd5be6c7fc5f04474ae,
title = "Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer.",
abstract = "Pancreatic cancer is a highly aggressive malignancy, and improvement in systemic therapy is necessary to treat this frequently encountered metastatic disease. The current targeted agents used in combination with gemcitabine improved objective response rates, but with little or no improvements in survival and also increased toxicities in pancreatic cancer patients. Recently, we showed that the triterpenoid cucurbitacin B inhibited tumour growth in pancreatic cancer cells by inhibition of the JAK/STAT pathway, and synergistically increased antiproliferative effects of gemcitabine in vitro.",
author = "Iwanski, {Gabriela B} and Lee, {Dhong H} and Shlomit En-Gal and Doan, {Ngan B} and Brandon Castor and Marco Vogt and Melvin Toh and Carsten Bokemeyer and Said, {Jonathan W} and Thoennissen, {Nils H} and Koeffler, {H Phillip}",
year = "2010",
language = "Deutsch",
volume = "160",
pages = "998--1007",
journal = "BRIT J PHARMACOL",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "4",

}

RIS

TY - JOUR

T1 - Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer.

AU - Iwanski, Gabriela B

AU - Lee, Dhong H

AU - En-Gal, Shlomit

AU - Doan, Ngan B

AU - Castor, Brandon

AU - Vogt, Marco

AU - Toh, Melvin

AU - Bokemeyer, Carsten

AU - Said, Jonathan W

AU - Thoennissen, Nils H

AU - Koeffler, H Phillip

PY - 2010

Y1 - 2010

N2 - Pancreatic cancer is a highly aggressive malignancy, and improvement in systemic therapy is necessary to treat this frequently encountered metastatic disease. The current targeted agents used in combination with gemcitabine improved objective response rates, but with little or no improvements in survival and also increased toxicities in pancreatic cancer patients. Recently, we showed that the triterpenoid cucurbitacin B inhibited tumour growth in pancreatic cancer cells by inhibition of the JAK/STAT pathway, and synergistically increased antiproliferative effects of gemcitabine in vitro.

AB - Pancreatic cancer is a highly aggressive malignancy, and improvement in systemic therapy is necessary to treat this frequently encountered metastatic disease. The current targeted agents used in combination with gemcitabine improved objective response rates, but with little or no improvements in survival and also increased toxicities in pancreatic cancer patients. Recently, we showed that the triterpenoid cucurbitacin B inhibited tumour growth in pancreatic cancer cells by inhibition of the JAK/STAT pathway, and synergistically increased antiproliferative effects of gemcitabine in vitro.

M3 - SCORING: Zeitschriftenaufsatz

VL - 160

SP - 998

EP - 1007

JO - BRIT J PHARMACOL

JF - BRIT J PHARMACOL

SN - 0007-1188

IS - 4

M1 - 4

ER -